AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi

SVB Leerink analyst Geoffrey Porges predicts $3 billion in peak sales for AbbVie's Skyrizi. (AbbVie)

Move over, Johnson & Johnson—AbbVie just joined the party with a direct competitor to Tremfya, and analysts say it might just be best-in-class.

Late Tuesday, the FDA greenlighted closely watched psoriasis prospect Skyrizi, the first IL-23 drug to hit the market after Tremfya and Sun's Ilumya. AbbVie touted its $88,500 first-year price on the new med—inclusive of two starter doses—and its $59,000 maintenance-dose price by saying it'll offer “broad and rapid access for patients.”

The annual maintenance price of Skyrizi, which is administered four times yearly, "is lower than the most widely-prescribed biologic treatments for moderate to severe plaque psoriasis,” a spokeswoman wrote by email.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

To set Skyrizi apart, AbbVie will also be pointing to a wealth of clinical data. Skyrizi “should benefit from … best-in-category efficacy,” SVB Leerink analyst Geoffrey Porges wrote in a Wednesday note to clients, calling out “stellar” phase 3 results that showed Skyrizi could clear skin lesions by 90% in up to three-quarters of patients within a week. And the AbbVie drug did that with less frequent dosing than Tremfya, which requires maintenance doses every eight weeks.

Of course, AbbVie won't just have to worry about its fellow IL-23 drugmaker. The IL-17 drug class—which now comprises Novartis’ Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq—is part of the next-gen psoriasis picture, too, as is IL-12/23 competitor Stelara from J&J and Celgene's pill Otezla.

And then there are the anti-TNF giants, led by AbbVie’s own Humira. With biosimilars on their way in that class—and Humira copies due in 2023—AbbVie is hoping Skyrizi can win patients over before the copycat meds can take hold.

And the way Porges sees it, use of anti-TNFs in psoriasis “should decrease as patients move to these new, more efficacious therapies." He figures Skyrizi will peak at $3 billion, a not-too-shabby figure, though it does fall short of AbbVie’s own $5 billion forecast for 2025.

RELATED: Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's

AbbVie isn’t expecting all of Skyrizi's sales to come from psoriasis, though. It’s anticipating $1.5 billion from inflammatory bowel disease, and to that end, Skyrizi is in phase 3 for both Crohn’s and ulcerative colitis. Data from those trials are set to roll out over the next few years.

Skyrizi also has a shot to become “an important drug in psoriatic arthritis,” Porges wrote; it's also in phase 3 for that condition.

Altogether, Skyrizi poses a threat across the psoriasis landscape, the analyst predicted. “In addition to slowing the growth of Taltz and Cosentyx and eroding the residual revenue for TNFs, longer term, we expect potent biologicals such as Tremfya and Skyrizi to threaten the robust growth trajectory of even Celgene’s Otezla,” he said.

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.